Novo Nordisk A/S $NVO Shares Sold by Inspire Trust Co. N.A.

Inspire Trust Co. N.A. reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 42.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,000 shares of the company’s stock after selling 15,000 shares during the quarter. Inspire Trust Co. N.A.’s holdings in Novo Nordisk A/S were worth $1,018,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $25,000. Strengthening Families & Communities LLC purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $30,000. WealthCollab LLC lifted its holdings in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares in the last quarter. Finally, American National Bank & Trust purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $28,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $45.51 on Friday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company has a 50 day moving average price of $40.81 and a 200 day moving average price of $46.38. The firm has a market capitalization of $203.19 billion, a price-to-earnings ratio of 10.68, a price-to-earnings-growth ratio of 3.97 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion during the quarter. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.46 EPS for the current year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk highlighted new cardiometabolic pipeline data, including Phase 3 results for CagriSema, and said it will present 40 abstracts at the upcoming ADA Scientific Sessions, reinforcing the company’s growth pipeline. Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
• Positive Sentiment: Some commentary argues Novo Nordisk may be undervalued after recent earnings strength and a slightly raised full-year outlook, suggesting the stock could still have room to recover if execution improves. Novo Nordisk (NVO) Among Our Most Undervalued Foreign Stocks to Buy Now
• Neutral Sentiment: At a Deutsche Bank conference, Novo said its oral semaglutide launch patterns are not yet matching the fast uptake seen in injectables, and the broker kept a Hold rating, which points to execution uncertainty rather than a major new setback. Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables
• Negative Sentiment: CVS Caremark’s expanded coverage for Lilly’s Zepbound and weight-loss pill improves patient access for a key rival, potentially pressuring Novo Nordisk’s competitive position in the obesity-drug market. CVS Caremark adds Zepbound and Foundayo to formulary
• Negative Sentiment: Broader reports that CVS is restoring coverage for Lilly’s obesity drugs strengthen the perception that Novo Nordisk faces tougher competition for insurer access and market share. CVS Restores Coverage for Lilly’s Zepbound

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. The Goldman Sachs Group reissued a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Finally, Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.